11:50 AM EST - SemBioSys Genetics Inc. : announced that its product and platform development collaboration agreement with Tasly Pharmaceutical Co., Ltd of Tianjin, China, and its wholly owned subsidiary Tasly US have received all necessary Chinese (People's Republic of China and local Chinese Government) approvals and the business license for the newly formed Company based in Tianjin, China, Tasly-SemBioSys Bio-Pharmaceutical, Technology Co., Ltd., to commercialize near-, medium- and long-term healthy living, nutritional, and pharmaceutical products utilizing Tasly and SemBioSys' plant-based technology and expertise. SemBioSys Genetics Inc.
shares T.SBS are trading up $0.075 at $0.13.
